Simplify Asset Management Inc. Trims Stock Holdings in Zevra Therapeutics, Inc. $ZVRA

Simplify Asset Management Inc. lessened its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 71.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,365 shares of the company’s stock after selling 104,635 shares during the quarter. Simplify Asset Management Inc. owned 0.08% of Zevra Therapeutics worth $380,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Russell Investments Group Ltd. grew its position in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares in the last quarter. Creative Planning bought a new position in Zevra Therapeutics during the 2nd quarter valued at $92,000. Quarry LP bought a new position in Zevra Therapeutics during the 3rd quarter valued at $103,000. Finally, Qube Research & Technologies Ltd acquired a new position in Zevra Therapeutics during the 2nd quarter worth $99,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

ZVRA opened at $10.03 on Monday. The firm has a market cap of $592.97 million, a price-to-earnings ratio of 5.04 and a beta of 0.88. Zevra Therapeutics, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $13.16. The company’s 50-day moving average price is $10.04 and its 200 day moving average price is $9.26.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Research analysts anticipate that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZVRA. Weiss Ratings cut shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday. BTIG Research began coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective for the company. Guggenheim increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.